Zonisamide is a voltage-dependent sodium channel and T-type calcium channel blocker, used as an antiepileptic drug.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||42 mg/mL in DMSO|
Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study.
Murata M, et al. Mov Disord. 2015 Sep;30(10):1343-50. PMID: 26094993.
|Related Sodium Channel Products|
CNV1014802(GSK-1014802) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor.
Vinpocetine is a selective inhibitor of voltage-sensitive sodium channel for the treatment of stroke, vascular dementia and Alzheimer's disease.
Tetracaine is a topical local anesthetic for the eyes; works by interfering with entry of sodium ions into nerve cells.
Rufinamide is a voltage-gated sodium channel blocker, used an anticonvulsant medication.
Proparacaine HCl is a voltage-gated sodium channels antagonist with ED50 of 3.4 mM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.